77% (13 out of 17) of p18mt;Gata3+/- mammary tumors were positive for EMT markers including fibronectin (Fn), vimentin (Vim), CD29, and EMT-TFs in 2-60% of the tumor cells. This evidence concerns the gene GATA3 and breast cancer.